

Table S1. Clinical Application of JAK inhibitors in Inflammatory Bowel Diseases and related conditions.

JAK inhibitor	Approved indications	Potential applications
Tofacitinib	FDA, Australia and EMA approved for treatment of moderate to severe ulcerative colitis (UC)	As salvage therapy for Acute Severe Ulcerative Colitis (ASUC); As part of a combination therapy for refractory inflammatory bowel disease (IBD); Treatment for ankylosing spondylitis, peripheral arthritis and limited reports on benefits on uveitis
Upadacitinib	FDA and EMA approved for treatment of moderate to severe ulcerative colitis (UC) FDA approved for treatment of moderate to severe Crohn's disease (CD)	As salvage therapy for Acute Severe Ulcerative Colitis (ASUC); Treatment for fistulizing Crohn's disease; Reduction of extraintestinal manifestations i.e. anemia, peripheral and axial neuropathy
Filgotinib	Treatment of moderate to severe ulcerative colitis (UC) in the UK, EU and Japan	Treatment of fistulizing perianal Crohn's disease